Articles related to SCHIZOPHRENIA

The new chemical entity is an atypical antipsychotic and the active metabolite of iloperidone (Fanapt). Its ability to cross the blood-brain barrier likely contributes to iloperidone’s clinical effects.

“For most patients in the early stages of schizophrenia, symptomatic remission can be achieved using a simple treatment algorithm comprising the sequential administration of amisulpride and clozapine.” — Leucht et al, J Clin Psychiatry 2026

“Evenamide has the potential to treat the symptoms of schizophrenia more broadly, addressing also those poorly managed by the currently available antipsychotics.” — Ravi Anand, MD, Therapeutic Advances in Psychopharmacology

Clozapine did not show superior efficacy compared to second-generation antipsychotics in treatment-resistant schizophrenia.

Expert psychiatric nurse practitioners stress the importance of familiarity with product inserts for each long-acting injectable antipsychotic to effectively manage missed doses in schizophrenia treatment.

Erzofri offers a new once-monthly injectable option for treating schizophrenia and schizoaffective disorder, potentially improving medication adherence for some patients.